T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of 1 of the following hematologic malignancies:
• * Acute myeloid leukemia (AML), meeting 1 of the following criteria:
• * In first complete remission (CR1), meeting 1 of the following criteria:
• * Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR), defined as 1 of the following:
• * Complex karyotype \[≥ 3 abnormalities\]
• * inv(3) or t(3;3)
• * t(6;9)
• * t(6;11)
• * Monosomy 7
• * Trisomy 8, alone or with an abnormality other than t(8;21), t(9;11), inv(16), or t(16;16)
• * t(11;19) (q23;p13.1)
• * Failed to achieve CR after primary induction chemotherapy
• * Secondary AML
• * In second or subsequent remission (CR2 or greater)
• * Acute lymphoblastic leukemia, meeting 1 of the following criteria:
• * In CR1, meeting 1 of the following criteria:
• * Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, FISH, or PCR, defined as the following:
• * Translocations involving 11q23, t(9;22), or bcr-abl rearrangement
• * Failed to achieve CR after primary induction chemotherapy
• * In CR2, if CR1 was \< 12 months
• * In CR3 or greater
• * Myelodysplastic syndromes (MDS)
• * INT-2 or high-risk by International Prognostic Scoring System
• * No MDS with Fanconi anemia
• * Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:
• * Accelerated phase with treatment failure after imatinib mesylate
• * Blast phase
• * Myeloproliferative disorders, meeting 1 of the following criteria:
• * Agnogenic myeloid metaplasia with adverse-risk features, meeting at least 2 of the following criteria:
• * Hemoglobin \< 10 g/dL or \> 10g/dL if transfusion-dependent
• * WBC \< 4,000/mm\^3 OR \> 30,000/mm\^3 OR requires cytoreductive therapy to maintain WBC \< 30,000/mm\^3
• * Abnormal cytogenetics, including +8, 12p-
• * Polycythemia vera or essential thrombocythemia in transformation to secondary AML
• * Myelodysplastic/myeloproliferative disease
• * Chronic myelomonocytic leukemia
• * Hodgkin's lymphoma or non-Hodgkin's lymphoma
• * Refractory lymphoma with progressive disease during combination chemotherapy
• * Relapse after OR ineligible for autologous stem cell transplantation (SCT)
• * Chronic lymphocytic leukemia
• * Treatment failure\* after fludarabine, chlorambucil, and at least 1 other salvage regimen
• * Prolymphocytic leukemia (PLL), meeting 1 of the following criteria:
• * T-PLL
• * Treatment failure\* after alemtuzumab and at least 1 other regimen
• * B-PLL
• * Treatment failure\* after fludarabine and at least 1 other salvage regimen
• * Multiple myeloma, meeting 1 of the following criteria:
• * Relapse after autologous SCT
• * Plasma cell leukemia
• * Adverse cytogenetics, defined as 1 of the following:
• * del(13q) = 11q translocation NOTE: \*Treatment failure is defined as relapse within 6 months OR failure to achieve remission
• Less than 10% blasts in bone marrow and no circulating blasts in peripheral blood for the following diagnoses:
• * Primary or secondary leukemia
• * Refractory anemia with excess blasts
• * CML
• * Other eligible diagnosis in transformation to acute leukemia
• Expected survival of approximately 1 year or less with conventional therapy
• No active CNS involvement by malignancy\*
• * Prior CNS involvement with no current evidence of CNS malignancy allowed NOTE: \*Active CNS malignancy is defined by lymphoma: tumor mass on CT scan or leptomeningeal disease OR leukemia: blasts present on cerebrospinal fluid cytospin
• Availability of a donor who is a sibling, parent, or offspring who shares 1 full haplotype (HLA-A, -B, or -DR)
• * Recipient and donor must have at least a 2-antigen disparity in either the host-versus-graft or graft-versus-host direction
• * Parent or offspring donor who is mismatched for a single HLA antigen (i.e., 5/6 HLA) is allowed
• * No sibling donor who is 6/6 HLA-matched OR mismatched for a single HLA antigen (i.e., 5/6 HLA)
• * No unrelated donor identified in a prior or current National Marrow Donor Program registry search
• PATIENT CHARACTERISTICS:
• Age
• 18 to 55
• Performance status
• ECOG 0-2 OR
• Karnofsky 60-100%
• Life expectancy
• At least 3 months
• Hematopoietic
• See Disease Characteristics
• Absolute neutrophil count ≥ 1,000/mm\^3\*
• Platelet count ≥ 20,0000/mm\^3\* (without transfusion) NOTE: \*Lower values may be accepted at the discretion of the principal investigator or study chairperson if due to bone marrow involvement by malignancy
• Hepatic
• ALT and AST ≤ 2.5 times upper limit of normal (ULN)\*
• Bilirubin ≤ 2.5 times ULN\*
• Unconjugated hyperbilirubinemia consistent with Gilbert's syndrome allowed
• No chronic active hepatitis B infection
• * Hepatitis B core antibody positive allowed provided patient is surface antigen negative and has no evidence of active infection
• No hepatitis C viral infection
• * Seronegative for anti-hepatitis C antibody and detectable hepatitis C viral RNA by reverse transcriptase-polymerase chain reaction assay NOTE: \*Higher levels may be accepted at the discretion of the principle investigator or study chairperson if such elevations are due to liver involvement by malignancy
• Renal
• Creatinine ≤ 1.5 mg/dL OR
• Creatinine clearance ≥ 50 mL/min
• Cardiovascular
• LVEF ≥ 45%
• Pulmonary
• DLCO ≥ 50% of expected value (corrected for blood hemoglobin level and alveolar volume)
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 year after study participation
• HIV negative
• No active infection not responding to antimicrobial therapy
• No psychiatric disorder that would preclude study compliance or informed consent
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• At least 2 weeks since prior monoclonal antibody therapy
• Chemotherapy
• See Disease Characteristics
• At least 2 weeks since prior systemic chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• Recovered from all prior therapy
• No administration of tyrosine kinase (TK) inhibitors, including imatinib mesylate and dasatinib, during the conditioning regimen; TK inhibitor administration may resume 28 days after transplantation